Rigel Pharmaceuticals | RIGL - Les Intérêts Débiteurs Sur La Dette





Les Intérêts Débiteurs Sur La Dette Changement Date
Agenus USD 14.67M 1.35M 2026-03
Amgen USD 95.64B 94.98B 2026-06
Anika Therapeutics 183.47M 4.09M 2026-06
Arrowhead Research USD 24.56M 716K 2026-06
AstraZeneca USD 340M 144M 2026-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Daiichi Sankyo JPY 3.57B 1.4B 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Halozyme Therapeutics USD 5.59M 80K 2026-06
Heron Therapeutics USD 600K 100K 2024-12
Intrexon USD 2K 5K 2024-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Karyopharm Therapeutics USD 12.55M 66K 2026-03
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
MacroGenics USD 4.89M 1.55M 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 667M 4M 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sangamo BioSciences 97.56M 11.39M 2025-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Veracyte USD 2K 1000 2023-12